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ABSTRACT 
Huntington’s disease is a neurodegenerative disease which is caused by dominantly inherited cytosine-adenine-guanine trinucleotide repeat 
expansion in the huntingtin gene of chromosome 4. Present survey reveals 2.7 per 100000 people are affected by huntington’s disease worldwide. 
The symptoms present with these patients are progressive motor, cognitive and psychiatric disorders. The early symptoms are chorea and loss of 
balance. This review aims to observe the present data available concerning huntington’s disease, symptoms, age of onset, risk factors, benefits of 
early diagnosis and genetic attribution. There is no cure for the disease. The article searched, selected and reviewed were from google scholar, 
medscape, NIH MedlinePlus, PubMed database using MeSH terms huntington’s disease, recent therapeutic advancement from 2003 to July 2021 
with no language restriction and additional studies were included from the reference lists of relevant articles. The present review provides clinical 
features, diagnosis, symptomatic management and ongoing research. Hence this review will have an impact to create awareness for the society and 
researchers to find future treatment for Huntington’s disease. 
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INTRODUCTION 
Huntington disease (HD) is a highly defective neurodegenerative 
disease which includes symptoms like progressive motor, cognitive 
and psychiatric disorders. It occurs by the repetition of cytosine, 
adenine and guanine (CAG) trinucleotide on the chromosome 4p16.3 
in the huntingtin gene [1]. This huntingtin gene gets translated into a 
mutant huntingtin protein (mHTT) [2]. In HD the symptoms are 
analogous to several other diseases. The family history plays a major 
role in HD patients, though there are 1-3% patients that have no 
family history [3]. There is a 50% chance of inheriting the huntingtin 
gene from parents to children. Inheriting the gene develops the 
disease [4,5]. HD can be classified into Adult onset huntington’s 
disease and Juvenile Huntington’s disease (JHD). Adults in the long 
run develop the symptoms in their mid 30s and 50s whereas 
symptoms of JHD are alike to Parkinson’s disease which constitute 
about 5% of HD cases [6]. The learning difficulties at school are the 
first sign and the majorities have epileptic fits. In HD 75% of father 
plays a major role in transmitting the disease to their children [7]. 
Nearly 2.7 per 100000 people are affected by HD worldwide. The 
patients with more CAG repeats exhibit this disease. This review is 
to find the aetiology, pathophysiology, types of diagnostic tests, 
clinical classification, management and ongoing research for 
management of HD [8, 9]. 
  
, 
Fig. 1: Schematic demonstration of gene mutation causing Huntington’s disease [10]. 1. Cytosine, adenine, and guanine (CAG) 
trinucleotide repeats on the short arm of chromosome 4p16.3 in the Huntingtin (HTT) gene having less than 36 repeats. 2. Expansion of 
unstable trinucleotide repeats 36 and above on HTT gene causes huntington’s disease 
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Aetiology and pathophysiology 
HD is mainly caused by elongation of CAG repeats of chromosome 
4p16.3 in the huntingtin gene. Patients affected with HD can be 
identified by genetic testing because HD is linked with the number of 
CAG repeats [11]. Patients with 36 repeats or more are affected by 
this disease. Whereas in JHD the CAG repeats are more than 55 
predominantly. The length of CAG from 29 to 35 does not cause the 
disease but it can lengthen in the generations. The male parent is the 
major cause for inheriting the disease [9].  
The majority of signal in HD occurs within the neostriatum. The 
degrees of atrophy depends upon pathological grade in various 
regions such as basal ganglia, frontal cerebral cortex, globus pallidus, 
thalamus, subthalamic nucleus, substantia nigra, and cerebellum 
[12]. In mouse model the pathophysiology was studied and it was 
observed that in early HD there is an increase in inhibitory input 
with a little change in excitatory input to pyramidal neurons but in 
late HD there is a marked decrease in inhibitory inputs to pyramidal 
neurons and a concomitant increase in excitation. In early HD the 
dopamine inputs to direct medium spiny neurons increase both 
excitatory and inhibitory inputs via a presynaptic effect. But there is 
a decrease in indirect receptor function on indirect pathway medium 
spiny neurons, but no net presynaptic change. An increase in evoked 
excitatory post-synaptic currents occurs that is probably mediated 
post synaptically. In late HD there is a decrease in excitation to both 
direct and indirect medium sized-spiny neurons which is probably 
due to a disconnection from excitatory synaptic inputs. There also is 
an increase in inhibitory input, but only to indirect medium sized-
spiny neurons [9].  
Age of onset 
There are 2 types of onsets. The early onset occurs between the age 
of 20 to 30 y whereas the late onset is between 30 to 50 y. The 
length of the CAG repeat in the late onset is 40 to 49 whereas in early 
onset the repeat is more than 50. The JHD occurs at the age below 21 
and it constitutes about 5% of the cases [13, 14]. The lifetime of the 
Huntington’s disease is 15-20 y, it also varies depending upon the 
care [1]. The shortening of the telomeres leads to several 
neurodegenerative diseases. HD leukocytes have the shortest 
telomeres, among all the neurodegenerative diseases [2]. The 
following table 1 represents the presence or absence of HD.  
 
Table 1: Presence or absence of HD depending on CAG repeats 
CAG repeats (length) Type Presence/absence References 
>60 Juvenile Presence of HD [1,5,7] 
Above 39 Adult onset Presence of HD [1,5,7] 
36-39 Late onset (adult) Are susceptible to HD [1,5,7] 
10-26 - Absence [1,5,7] 
 
Symptoms 
Table 2: Types of symptoms and indications 
Types Indications References 
Motor symptoms Chorea, dystonia, loss of postural reflexes, bradykinesia and rigidity  [15-18] 
Cognitive symptoms Disorganization as a result of difficulties with planning, initiating, and organizing thoughts, activities, and 
communication; perseveration; impulsivity; perceptual distortions; lack of insight; distractibility; 
difficulty in learning new information  
[15-18] 
Psychiatric symptoms Depression, obsessive-compulsive disorders, anxiety, irritability, apathy, hypersexuality (uncommon), 
psychosis (uncommon)  
[15-18] 
Metabolic symptoms Weight loss and sleep disturbance  [6] 
Miscellaneous Dysphasia (combination of motor and language difficulties), dysphagia (combination of motor problems, 




The motor symptoms that occur in HD can be diagnosed by the total 
motor score (TMS) of unified HD rating scale, though TMS does not 
depict the precise changes when group of people with HD are 
analyzed. The quantitative motor tests are more accurate [19].  
Types of diagnostic tests  
Generally, three types of diagnostic testing are used to manifest the HD.  
Type I: By collecting patient history and neurological examination. 
For this a neurologist will conduct a detailed interview to obtain a 
pedigree to rule out other conditions. And he will do physical 
examination such as review reflexes, balance, movement, muscle 
tone, hearing, walking, and mental status. After analysing type I the 
individual may be referred to specialists such as psychiatrists, 
genetic counsellors, clinical neuropsychologists, or speech 
pathologists for specialized management and/or diagnostic 
clarification [1, 4].  
Type II: Diagnostic imaging is normally conducted if a person’s 
family history and genetic testing are inconclusive. In this condition 
the physician may recommend brain imaging, such as computed 
tomography or magnetic resonance imaging. As the disease 
progresses, these scans typically reveal shrinkage in parts of the 
brain and enlargement of fluid-filled cavities within the brain called 
ventricles. These changes do not necessarily indicate HD, because 
they can occur in other disorders [1, 4].  
Type III: Genetic tests. Genetic testing can confirm to determine a 
person’s chance of developing or passing on a genetic disorder. 
Genetic testing makes it possible to predict with a higher degree of 
certainty if someone will develop HD. The most accurate and 
effective technique for diagnosis HD is direct genetic test which 
counts the number of CAG repeats in the HD gene, using DNA taken 
from a blood sample. The presence of 36 or more repeats supports a 
diagnosis of HD. A test result of 26 or fewer repeats rules out HD. 
The prenatal exclusion testing requires a sample of DNA from a 
parent or relative to identify marker HD gene and to determine if a 
fetus has inherited a chromosome 4 mutation from an affected 
grandparent. This method is used for prenatal testing [1, 4].  
Patients at risk of HD often test before making decisions about 
marriage or starting their career. The emotions cannot be 
determined and can lead to some adverse reactions. In some cases, 
the patient who is in a serious relationship and is about to marry will 
have to learn what to tell the mate about his/her genetic disorder. 
For these young people this seems to end their career and it leads to 
a disappointment [20].  
Quality of life 
HD has an intense effect on the quality of life. The onset of symptoms 
starts with the loss of employment in the early stages of HD. The 
patient will need a 24 h care and support at the final stages [20]. 
Physical fitness is necessary and regular exercise can improve the 
quality of life [21]. Patients with HD at the early stages are not aware 
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of the choreiform movements, it affects while doing the daily 
functioning activities. In recent studies the gait impairments, 
bradykinesia, and choreiform movements are the important health 
issues that damage the quality of life of patients. The doctors help in 
consulting the patients and giving them treatment when chorea 
interferes with the daily activities. The dopamine depleting drugs, or 
antipsychotics drugs are given to the patient to treat chorea [22].  
Management guidelines 
To manage symptoms and improve quality of life treatments are 
needed. Unfortunately, there is no drug available to cure HD. But 
both drug based and non-drug based treatments are practiced to 
slow down the disease progression. Drugs commonly used for 
symptomatic management are olanzapine, risperidone, quetiapine, 
clozapine, and aripiprazole for psychosis [23]. For depression, 
anxiety, obsessive-compulsive symptoms, irritability, aggression 
drugs like citalopram, fluoxetine, paroxetine, mirtazapine and 
venlafaxine are prescribed. Zopiclone and zolpidem are given for 
altered sleep-wake cycle [24]. Anticonvulsants like sodium 
valproate, lamotrigine, and carbamazepine are used as mood 
stabilizers. Antipsychotic drugs, antidepressant and tranquilizers are 
used to control HD [18].  
Many non-drug based measures are effective in the management of 
HD, and these are often more helpful than drugs. The physicians, 
nurses, physiotherapists, speech and language therapists and other 
health care workers play a major role on these patients. Though the 
pharmacological effect is not up to the mark both pharmacological 
and non-pharmacological treatments are necessary. Because of the 
limited evidence, their use is based on extensive clinical experience. 
Physiotherapy is normally done to optimize and strengthen gait and 
balance, and to assess for walking aids. Occupational therapy can be 
considered to modify home environment and improve safety and 
weighted wrist bands to combat limb chorea. Occupational therapy 
is also advisable to overcome apathy and difficulty in initiating 
activities. Apart from these appoint experienced healthcare 
professionals to help at home, residential or nursing home care, day 
centres to maintain social interactions. Speech and language therapy 
is practiced optimizing speech and to advise on safest food 
consistencies at different stages of disease. Develop strategies to 
deal with cognitive and emotional challenges of disease using 
counselling or cognitive behavioural therapy. Exercise plays a major 
role in controlling the disease [25]. Physicians are recommended 
that patients are referred to a specialist multidisciplinary HD clinic 
wherever it is possible, so that they can access care from healthcare 
professionals experienced in the management of the disease. 
Support from professionals in the community remains vital, and 
optimal care is typically provided by a multidisciplinary team that 
includes some or all the following: general practitioners, 
neurologists, geneticists, psychiatrists, physiotherapists, 
occupational therapists, speech and language therapists, dietitians, 
community mental health teams, and social workers. Presently HD 
advisers are available throughout England and Wales to support 
patients and their families, and to provide educational input for 
healthcare professionals caring for people with the disease [26]. As 
the HD progress the dysphagia occurs. Hence it is recommended that 
a person with HD and their carers seek professional advice to make 
sure their diet is nutritious, with lots of calories and easy to eat [27]. 
  
Table 3: Therapeutic approaches to Huntington’s disease developed by the pharmaceutical companies in current or future multi-site 
clinical trials 
  Type of 
approach 
Drug/No drug and mode of action Clinical trial Hope to society References 
UniQure  Genetic 
therapies to 
lower huntingtin  
AMT-130: It is delivered by a brain 
surgery and uses a virus to spread the 
treatment throughout the brain. The 
treatment targets the genetic messages 
of both harmful and normal huntingtin 
protein, lowering both. 
Phase I/II safety 
trial 
 
Experimental data in small, 
large animals and three 
publications which together 
show good safety, stability, 
and spread of AMT-130 
throughout the brain. 
[28, 29] 
Novartis  A pill to lower 
huntingtin 
Branaplam: It was developed to treat 
the neurological disorder spinal 
muscular atrophy, could be repurposed 
to treat HD. 
Received orphan 
drug status. Used 
in a clinical trial to 
treat people with 
HD. 





A pill to lower 
huntingtin 
PTC518: It reduces the levels of 
huntingtin in different animal and lab 
models of HD. 
Phase I clinical 
trial in healthy 
people is currently 
underway to 
investigate the 
safety of PTC518. 
Provisional data shared at a 
recent investor meeting 
looks more promising and 
indicates this therapy is 
working as expected, and no 
dangerous side effects have 









RNAi therapies for different 
neurodegenerative diseases, including 
Huntington’s disease. RNAi therapies 
work in a similar way to anti-sense 
oligonucleotides by interfering with a 
specific genetic message to lower the 
levels of a specific protein. 
- Atalanta makes a special 
form of RNAi which has a 
branched structure and is 
able to spread well 
throughout the brain, so 
they think this will be good 
for treating brain related 
diseases. 
[32] 
Locanabio  New genetic 
technologies to 
treat HD 
Aims to target genetic messages which 
contain the instructions for cells to 
make disease causing proteins, such as 
the harmful form of huntingtin. 
- More details yet to come 








ANX005: Therapy targets part of the 
immune system. People with HD seem 
to have overactive complement 
systems that leads to nerve cell damage 
and changes to the connections 
between brain cells. This therapy aims 
to stop the complement system from 
switching on too much. 
Phase II trial 
underway for 
Huntington’s 
patients with their 
drug 
Expecting better outcome. [34,35] 
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  Type of 
approach 
Drug/No drug and mode of action Clinical trial Hope to society References 
Prilenia  Stopping the 
complement 
system 
Pridopidine: Action on sigma 1 
receptor. 
Phase III trial 
 






TTX-3360: Targeting DNA damage 
repair processes, with the aim of 
slowing or halting the progression of 
HD. Aims to track HD progression over 
time and further explore CAG repeat 
expansion along with the development 
of symptoms. The main goal is to 
determine the best time to treat. 






Targeting DNA damage repair 
processes, with the aim of slowing or 
halting the progression of HD  







SAGE-718: developing and validating 
patient-reported outcome and it 
involves questions answered directly 
by patients, rather than measurements 
made by doctors. 
Phase I/II clinical 
trial 







Valbenazine: similar to treatments like 
tetrabenazine and deutetrabenazine 
and has already been approved for a 
disorder called tardive dyskinesia. 




effects on the 
movement 
symptoms of HD 
(chorea) 
Expecting better outcome. 
 
[28, 40, 41] 
 
Observational and local studies 
For understanding HD and identifying new aspects of HD biology to 
focus on for future drug development observational studies are also 
in progress. ENROLL-HD is an observational study for HD families 
that monitors how HD appears and changes in people over time [42]. 
Through a better understanding of HD, scientists hope they might 
learn how to make better medicines for HD. Clarity is a 
cerebrospinal fluid collection initiative to facilitate therapeutic 
development for HD [43, 44]. Researchers use the exact same 
methods to collect spinal fluid from participants all over the world, 
and these samples provide a window into how the nervous system is 
affected by HD. At present academic groups are also conducting 
research [PREDICT-HD] on a smaller scale population by collecting 
family survey and questionnaires, observing communication style 
and advising genetic testing to improve the quality of life by doing 
physical therapy and speech pathology regimens, or testing existing 
drug combinations or alternative therapies to improve side effects 
or sleep [45, 46]. 
CONCLUSION 
The rare and family disease (HD) has no cure as far now, but 
treatments can be given through both pharmacological and non-
pharmacological methods. Many organisations are there globally, 
and the clinical trials are on process. To perform the efficacy and 
safety of the drug right dose is required. More emphasis should be 
laid on clinical trials of this disease so that more efficient treatments 
of the disease could be done. Gene therapy can be optimistic. The 
screening of the embryo for the test tube baby must be enhanced in 
order to stop the family mutations (disease). It is perpetuity in 
family, to break this cloud that threatens the family in effort to bring 
them hope and optimism by doing this together with them as they 
volunteer to participate in trials it can be useful, though the 
outcomes are not known. There must be hope in patients, now it’s 
much more than expectations. Expectations lead to disappointment 
but with hope they can survive. Sharing their sorrow and 
disappointment can give them hope. The present review would be 
beneficial for the researchers working in the field of development of 
new drugs for the treatment of HD and to look forward for more 
effective strategies to eradicate this difficulty completely. In next 20 
y we see that this disease will be cured at the initial stages, within 
days they are born. 
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